Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX
Affiliation auteurs | !!!! Error affiliation !!!! |
Titre | Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX |
Type de publication | Journal Article |
Year of Publication | 2020 |
Auteurs | Fumet J-D, Vincent J, Bengrine L, Hennequin A, Granconato L, Palmier R, Ghiringhelli F |
Journal | ANTICANCER RESEARCH |
Volume | 40 |
Pagination | 4011-4015 |
Date Published | JUL |
Type of Article | Article |
ISSN | 0250-7005 |
Mots-clés | Capecitabine, Chemotherapy, cisplatin, Docetaxel, Gemcitabine, pancreatic cancer |
Résumé | Background/Aim: The aim of this monocentric study was to evaluate the efficacy and tolerability of a polychemotherapy regimen based on gemcitabine, docetaxel, capecitabine, cisplatin (PDGX) as second-line for advanced pancreatic cancer after FOLFIRINOX. Patients and Methods: Patients received FOLFIRINOX as first-line regimen were retrospectively identified between January 2016 and January 2019. After disease progression or unacceptable toxicity, patients eligible for second-line therapy were treated in our center by PDGX. Results: During this period, 18 patients received PDGX regimen as second-line therapy. Main grade 3 toxicities were hematologic, which required dose adaptation in 14/ 18 patients. No toxic death was observed. Median second-line progression-free survival (PFS) and overall survival (OS) were 2,91 and 5,3 months, respectively. Total OS from the initiation of first-line was and 11,9 months. Conclusion: Second-line PDGX regimen after FOLFIRINOX failure is feasible, with notable toxicity profile and is associated with poor clinical outcomes. |
DOI | 10.21873/anticanres.14395 |